Corrigendum to “PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis” [EBioMedicine 40 (2019) 290-304]

• Cristian Rodriguez-Aguayo,
• Emine Bayraktar,
• Cristina Ivan,
• Burcu Aslan,
• Junhua Mai,
• Guangan He,
• Lingegowda S. Mangala,
• Dahai Jiang,
• Archana S. Nagaraja,
• Bulent Ozpolat,
• Arturo Chavez-Reyes,
• Mauro Ferrari,
• Rahul Mitra,
• Zahid H. Siddik,
• Haifa Shen,
• Xianbin Yang,
• Anil K. Sood,
• Gabriel Lopez-Berestein

Affiliations

Cristian Rodriguez-Aguayo

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Emine Bayraktar

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Medical Biology, Faculty of Medicine, University of Gaziantep, Gaziantep 27310, Turkey

Cristina Ivan

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Burcu Aslan

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Junhua Mai

Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA

Guangan He

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Lingegowda S. Mangala

Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Dahai Jiang

Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Archana S. Nagaraja

Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Bulent Ozpolat

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Arturo Chavez-Reyes

Centro de Investigación y Estudios Avanzados del IPN, Unidad Monterrey, Apodaca, NL, CP. 66600, Mexico

Mauro Ferrari

Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA

Rahul Mitra

Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Zahid H. Siddik

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Haifa Shen

Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA

Xianbin Yang

AM Biotechnologies LLC, 12521 Gulf Freeway, Houston, TX 77034, USA

Anil K. Sood

Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Gabriel Lopez-Berestein

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Corresponding author.